| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 12th June 2019 | Allan L Goldstein | 228,000 | Bona fide gift | $0.00 | |
| 6th January 2019 | Allan L Goldstein | 208,912 | Conversion of derivative | $0.06 | $12,534.72 |
| 6th January 2019 | Joseph C Mcnay | 522,280 | Conversion of derivative | $0.06 | $31,336.80 |
Regene Rx Biopharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
RegeneRx Biopharmaceuticals, Inc. focuses on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.
Ticker: RGRX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 707511
Employees: 4
Exchange: US OTC
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Facebook sues two companies engaged in data scraping operations
1st October 2020
Goldman to buy GM's credit card unit for US$2.5 billion - WSJ
1st October 2020
